Document is current
Any future updates will be listed below
-
Authors
Ohama, Hideko
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Naganuma, Atsushi
Kosaka, Hisashi
Matono, Tomomitsu
Kuroda, Hidekatsu
Yata, Yutaka
Tanaka, Hironori
Nishikawa, Hiroki
Shibata, Hiroshi
Tada, Fujimasa
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Iijima, Hiroko
Kaibori, Masaki
Hiasa, Yoichi
Kumada, Takashi
- License Information
-
More Information
Article History
Received: 18 October 2023
Accepted: 31 October 2024
First Online: 2 January 2025
Declarations
:
: The entire study protocol was approved by the Institutional Ethics Committee of Ehime Prefectural Central Hospital (No.2022-46). After receiving official approval, this study was conducted as a retrospective analysis of database records based on the Guidelines for Clinical Research issued by the Ministry of Health and Welfare of Japan. All procedures were done in accordance with the declaration of Helsinki. The data were made anonymous before analysis to protect patient privacy. Written informed consent was obtained from all patients before treatment and this study received ethical approval for use of an opt-out methodology based on low risk to the participants.
: Atsushi Hiraoka, MD, PhD: lecture fees; AstraZeneca, Bayer, and Eli Lilly. Takashi Kumada, MD, PhD: lecture fees; Eisai. Toshifumi Tada, MD, PhD: Abbvie and Eisai. Takeshi Hatanaka, MD, PhD: Eisai. None of the other authors have potential conflicts of interest to declare.
